scholarly journals Differential genome-wide profiling of tandem 3' UTRs among human breast cancer and normal cells by high-throughput sequencing

2011 ◽  
Vol 21 (5) ◽  
pp. 741-747 ◽  
Author(s):  
Y. Fu ◽  
Y. Sun ◽  
Y. Li ◽  
J. Li ◽  
X. Rao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
Human Breast Cancer ◽  
High Throughput Sequencing ◽  
Human Breast ◽  
Normal Cells ◽  
Genome Wide

Abstract LB-180: A human breast cancer 3D spheroid platform for microscopy based high throughput screening

2020 ◽  
Author(s):  
Christine Gjerdrum Rines ◽  
Kara Gordon ◽  
Ranor Basa ◽  
Alyson Smith ◽  
Robert Oshima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
High Throughput Screening ◽  
Human Breast Cancer ◽  
Human Breast

scholarly journals Time-course analysis of genome-wide gene expression data from hormone-responsive human breast cancer cells

2008 ◽  
Vol 9 (Suppl 2) ◽  
pp. S12 ◽  
Author(s):  
Margherita Mutarelli ◽  
Luigi Cicatiello ◽  
Lorenzo Ferraro ◽  
Olì MV Grober ◽  
Maria Ravo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Time Course ◽  
Expression Data ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Genome Wide ◽  
Genome Wide Gene Expression

scholarly journals Silibinin in human breast cancer: Scope beyond placebo!

2017 ◽  
Vol 2 (2) ◽  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Inhibitory Action ◽  
Milk Thistle ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Normal Cells ◽  
Naturally Occurring ◽  
Preventive Activity

Chemotherapies for breast cancer generally have strong cytotoxicity and severe side effects. Thus, significant emphasis has been placed on combinations of naturally occurring chemo preventive agents. Silibinin is a major bioactive flavonolignan extracted from milk thistle with known chemo preventive activity in various organs. However, the mechanism underlying the inhibitory action of Silibinin in breast cancer has not been completely elucidated. Several investigations have been and are being conducted, to study the effect of Silibinin in human breast cancer cells and protective effect in normal cells. The aim of the present article is to review and summarize the physical properties, mechanism of action, pharmacokinetics, role and potential of Silibinin in breast cancer.

scholarly journals Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

2008 ◽  
Vol 68 (22) ◽  
pp. 9532-9540 ◽  
Author(s):  
Yuri Nikolsky ◽  
Evgeny Sviridov ◽  
Jun Yao ◽  
Damir Dosymbekov ◽  
Vadim Ustyansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Genome Wide

Gold nanoparticles conjugated L- lysine for improving cisplatin delivery to human breast cancer cells

2020 ◽  
Vol 18 ◽  
Author(s):  
Mahdieh Ganji ◽  
Fariba Dashtestani ◽  
Hoda Keshmiri Neghab ◽  
Mohammad Hasan Soheilifar ◽  
Fatemeh Hakimian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gold Nanoparticles ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Lethal Dose ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Normal Cells ◽  
Vis Spectroscopy

: An anticancer drug, cisplatin (CDDP) conjugated gold nanoparticles (GNPs) via L-Lysine (Lys) linker exhibiting a significant toxicity against cancer cells. The produced nanodrug (GNPs-Lys-CDDP) was charachterized by UV-Vis spectroscopy, dynamic light scattering (DLS), Zeta potentials and electron force microscopy. The cytotoxic efficacy of the GNPs-Lys-CDDP against human breast cancer cells (SKBR3) and normal cells (MCF-10A) was evaluatedby MTT assay. Cell apoptosis and morphology changes were assessed by flowcytometery and acridine orange/ethidium bromide (AO/EtBr) staining, respectively. It was found that the GNPs-Lys-CDDP with a size of 85 nm and negatively charged with a zeta-potential of about −25 mV could be taken up by tumor cells. A marked change in the UV spectrum of GNPs-LysCDDP compare to GNPs showed a strong absorption shift in the 525 nm region. The LD50 of GNPs-Lys-CDDP against SKBR3 (1 µg.ml-1), was found to be 8 times lower than that of naked CDDP against SKBR3 (8 µg.ml-1). The nanocomplex GNPs-Lys-CDDP also significantly increased the apoptosis of SKBR3 with the lowest cytotoxic effects on normal cells. This work indicates that GNPs effectively could decrease the lethal dose of CDDP to 87%. Hence, GNPs modified by Lys, could be a good nano-carrier for chemotherapeutic drugs.

Sign in / Sign up

Export Citation Format

Share Document